Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children

Related Experiment Video

Updated: Aug 29, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Dorie W Hoody1, Courtney V Fletcher

  • 1Antiviral Pharmacology Laboratory, School of Pharmacy, University of Colorado Health Sciences Center, Denver, 80206, USA.

Seminars in Pediatric Infectious Diseases
|January 16, 2004
PubMed

Insights

Pediatric human immunodeficiency virus (HIV) treatment requires combination antiretroviral therapy. Dosing regimens for children necessitate careful consideration due to incomplete pharmacokinetic data, impacting safe and effective care.

Area of Science:

  • Pediatric Pharmacology
  • Infectious Diseases
  • Antiretroviral Therapy

Background:

  • Children with human immunodeficiency virus (HIV) require combination antiretroviral therapy (ART) and drugs for opportunistic infections.
  • Current guidelines suggest adult treatment principles apply to pediatric HIV care.
  • However, limited pharmacokinetic and pharmacodynamic data exist for many adult ART agents in children.

Purpose of the Study:

  • To provide an overview of pediatric pharmacologic principles relevant to HIV treatment.
  • To review the pharmacologic characteristics of selected antiretroviral agents specifically in pediatric populations.
  • To offer guidance on designing effective drug dosing regimens for children with HIV.

Main Methods:

  • Review of existing literature on pediatric pharmacokinetics and pharmacodynamics of antiretroviral drugs.
  • Analysis of current treatment guidelines for pediatric HIV infection.
  • Discussion of challenges and considerations in pediatric antiretroviral drug dosing.

Main Results:

  • Significant gaps exist in the understanding of how antiretroviral agents are processed and affect children.
  • Clinicians often administer medications with incomplete knowledge of their pediatric pharmacologic properties.
  • Establishing safety and efficacy through large-scale pediatric clinical trials remains a challenge.

Conclusions:

  • Pediatric HIV treatment requires specialized pharmacologic considerations beyond adult protocols.
  • Further research is crucial to define optimal antiretroviral dosing and regimens for children.
  • This review aims to support clinicians in making informed therapeutic decisions for HIV-infected children.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...